Aclaris Therapeutics (ACRS) Gross Profit (2017 - 2026)

Aclaris Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 68.7% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $6.4 million (down 58.22% YoY), while the FY2025 annual figure was $5.7 million, down 63.99% from the prior year.
• Gross Profit was $1.6 million for Q1 2026 at Aclaris Therapeutics, up from $763000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $18.1 million in Q3 2022 to a low of $298000.0 in Q1 2022.
• Historically, Gross Profit has averaged $4.5 million across 5 years, with a median of $1.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Gross Profit surged 3131.25% in 2022, then sank 91.03% in 2025.
• A 5-year view of Gross Profit shows it stood at $6.9 million in 2022, then soared by 144.98% to $16.8 million in 2023, then tumbled by 49.5% to $8.5 million in 2024, then tumbled by 91.03% to $763000.0 in 2025, then soared by 109.83% to $1.6 million in 2026.
• The last three Gross Profit figures came in at $1.6 million (Q1 2026), $763000.0 (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.